Matches in Wikidata for { <http://www.wikidata.org/entity/Q104676416> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q104676416 description "clinical trial" @default.
- Q104676416 description "ensayo clínico" @default.
- Q104676416 description "ensayu clínicu" @default.
- Q104676416 description "klinisch onderzoek" @default.
- Q104676416 description "клінічне випробування" @default.
- Q104676416 description "կլինիկական փորձարկում" @default.
- Q104676416 description "临床试验" @default.
- Q104676416 name "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 name "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 type Item @default.
- Q104676416 label "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 label "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 prefLabel "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 prefLabel "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma." @default.
- Q104676416 P1050 Q104676416-9B570899-42D8-482D-A5B2-E2E62D5A74F3 @default.
- Q104676416 P1132 Q104676416-9283F566-8007-4D34-A682-D5FF6DDBEAD3 @default.
- Q104676416 P1476 Q104676416-4662CC82-8B0C-4392-AB43-584D11B31A27 @default.
- Q104676416 P1813 Q104676416-9EE01D82-0220-4DD5-A5CD-7C523B919383 @default.
- Q104676416 P2899 Q104676416-DF2084A9-27FC-411C-8B5B-ED57A9AA1B60 @default.
- Q104676416 P3098 Q104676416-9E5494DB-9E4E-44DA-8278-25BDEE7228B4 @default.
- Q104676416 P31 Q104676416-115B7A6E-4E66-4ABF-B1C8-EC1763D17E93 @default.
- Q104676416 P4844 Q104676416-075D0D9D-CCEC-4612-83ED-631807ADB4CC @default.
- Q104676416 P4844 Q104676416-B827A304-F543-4A86-87DA-FD19549EA361 @default.
- Q104676416 P580 Q104676416-EEDB5CB3-CFBA-4445-BB06-9976FAB1E494 @default.
- Q104676416 P582 Q104676416-ED18CF0E-4981-4ECB-820A-BAA4FCCBE321 @default.
- Q104676416 P6099 Q104676416-143F118D-F983-48F3-8EFC-B838AF5DB4D2 @default.
- Q104676416 P8005 Q104676416-1EBD4DDE-9583-40D8-B49F-FE2422C3E46C @default.
- Q104676416 P8363 Q104676416-D4813923-13C8-4E35-96E4-80A7D0192E44 @default.
- Q104676416 P1050 Q208414 @default.
- Q104676416 P1132 "+618" @default.
- Q104676416 P1476 "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma" @default.
- Q104676416 P1813 "InMIND" @default.
- Q104676416 P2899 "+18" @default.
- Q104676416 P3098 "NCT04680052" @default.
- Q104676416 P31 Q30612 @default.
- Q104676416 P4844 Q412323 @default.
- Q104676416 P4844 Q425681 @default.
- Q104676416 P580 "2021-01-30T00:00:00Z" @default.
- Q104676416 P582 "2023-06-30T00:00:00Z" @default.
- Q104676416 P6099 Q42824827 @default.
- Q104676416 P8005 Q76649614 @default.
- Q104676416 P8363 Q78089383 @default.